Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

BRAF/MEK Combinations Continue to Revolutionize Melanoma Landscape

Danielle Bucco
Published: Wednesday, Nov 01, 2017

Dr. Michael A. Postow

Michael A. Postow, MD
The BRAF/MEK inhibitor combination of dabrafenib (Tafinlar) and trametinib (Mekinist) was found to reduce the risk of relapse or death by 53% compared with placebo for patients with BRAF-mutant stage III melanoma, according to findings from the phase III COMBI-AD study.

during the 2017 World Congress on Melanoma, Postow, a medical oncologist specializing in melanoma at Memorial Sloan Kettering Cancer Center, discussed the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

OncLive: What are some promising treatments in the pipeline for patients with resected stage III melanoma?

Postow: Most of the treatments that are effective for resected stage III melanoma are drugs that have been shown to already be beneficial for patients with stage IV melanoma or unresectable stage III melanoma. For example, drugs such as PD-1 antibodies or BRAF and MEK inhibitors, either alone or in combination.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication